Wearable Defibrillator Market: Breaking a 20-Year Monopoly

On July 14, Kestra Medical Technologies announced two significant milestones. The company reported $95.1 million in fiscal 2026 revenue, representing 59% year-over-year growth, and secured up to $200 million in non-dilutive financing from Pharmakon Advisors.

Those announcements represent more than another successful financing. They suggest one of the fastest-growing companies in the wearable defibrillator market now has the resources to challenge one of medtech’s longest-standing competitive positions.

For nearly two decades, ZOLL’s LifeVest has dominated the wearable cardioverter defibrillator (WCD) category. Kestra’s accelerating commercial performance, combined with substantial non-dilutive capital, signals that the market may finally be entering a new phase.

The Wearable Defibrillator Market Is Becoming Competitive

Wearable cardioverter defibrillators provide temporary protection for patients at elevated risk of sudden cardiac death. Patients recovering from a heart attack or newly diagnosed with cardiomyopathy often wear these devices while physicians determine whether permanent therapy is necessary.

For years, the category remained largely unchanged.

The global WCD market is valued at approximately $298 million in 2026 and is projected to reach $535 million to $583 million by 2033. ZOLL’s LifeVest accounts for roughly 45% of global revenue and has operated with limited direct competition in the United States throughout most of its history.

Kestra’s ASSURE system is emerging as the strongest challenger. During fiscal 2026, the company reported 59% revenue growth, 57% growth in ASSURE prescriptions to 20,720, gross margin expansion from 40.5% to 51.4%, and its tenth consecutive quarter of margin improvement. The company also guided to approximately $137 million in revenue for the coming fiscal year.

Historically, broader adoption of WCDs has been constrained by two factors: garments that many patients found difficult to wear consistently and ongoing debate surrounding clinical effectiveness. Both dynamics are beginning to shift as new products enter the market.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/wearable-defibrillator-market-breaking-a-20-year-monopoly

Comments

Post a Comment

Popular posts from this blog

U.S. Medtech Market Growth: The Numbers Behind the Trends

The U.S. medtech market continues to be a dominant force globally, representing over 45% of the worldwide medtech revenue as of 2025. Despite recent concerns and headlines suggesting uncertainty, a deeper dive into the numbers tells a different story: one of resilience and steady expansion. Thanks to growing  surgical procedure volumes  and significant investments in innovation, the United States remains at the forefront of medtech development. In this article, we’ll explore the factors driving growth, key statistics, and the market’s long-term outlook for  medtech companies . U.S. Medtech Market Resilience Amidst Challenges For the past several decades, the United States has remained the largest market for medical devices worldwide. Its dominance in the field is attributed to several factors: a robust ecosystem of research and development, a highly engaged healthcare workforce, and the adoption of cutting-edge technologies like surgical robotics and AI-powered diagnostic...
Read more

The Weekly Recap 4/11/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

  Achieved ISO 13485 certification, the globally recognized standard for quality management systems for medical devices. The accreditation strengthens the company’s manufacturing readiness for its 4Degra bioabsorbable resin platform, supporting its commercial strategy and accelerating regulatory pathways toward clinical deployment. For more information visit here:  https://medium.com/@lifesciencemarketresearch/the-weekly-recap-4-11-25-lsi-alumni-achievements-driving-medtech-and-healthtech-forward-386e389bab3a
Read more

LSI Alumni Innovator Spotlight: CardiaCare CEO Amir Soltanianzadeh

Soltanianzadeh’s medtech journey has taken him from start-up entrepreneur, to investor, to CEO of CardiaCare: an innovative AI-based neuromodulation therapy company working to revolutionize atrial fibrillation treatment. In the midst of a Series A raise, he will be presenting at the March LSI USA ‘25 event in Dana Point, CA. For more information visit here:  https://mega.nz/file/LTxAHJII#mNylAswp3i9PhxvgGpM2f_pQtN9BnWR5z9rQQK2cluU  
Read more